Late treatment study
et al., medRxiv, doi:10.1101/2020.06.30.20143289 (Preprint)
Hydroxych loroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19
Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 patients, showing no significant differences (significant reduction in viral load is seen in both groups).
The groups are not comparable, with significant differences seen between hospitalized and non-hospitalized patients. 9 of 10 hospitalized patients were in the HC
Q group and only one in the control group. 2 additional control patients were added between the first and second version of this preprint (including the only hospitalzied control patient).
Please send us corrections, updates, or comments.